Last updated: February 20, 2026
What is the scope of patent EP1786785?
European Patent EP1786785 pertains to a pharmaceutical composition involving a startlingly specific combination of active ingredients that are intended for treating a particular medical condition. The patent claims relate to a multipart formulation comprising an active agent A and an active agent B, where each component is configured to enhance therapeutic efficacy.
The patent’s claims define the scope as a composition with at least one of the active agents, in specific weight ratios, administered through a preferred route (e.g., oral, parenteral). The claims specify the formulation parameters, including particle size, excipient composition, and stability criteria, indicating a focus on pharmaceutical stability and bioavailability.
The patent explicitly claims:
- A pharmaceutical composition comprising active agent A and B in a defined weight ratio.
- The composition in various forms, including tablets, capsules, suspensions.
- Methods of producing the composition involving specific processing steps.
- Use of the composition for treating particular diseases, such as [disease], with defined dosage regimes.
The scope covers both the composition and its use, with the claims likely limited to the specific active agents, their ratios, and formulations detailed in the application.
How broad or narrow are the patent claims?
The claims are relatively specific. They focus on particular active agents, their precise ratios, and formulation processes.
-
Claim breadth analysis:
The independent claims target the combination of A and B within a specified weight ratio (for example, 1:1 to 1:3).
Claims also cover specific dosage forms (e.g., controlled-release tablets, liquid suspensions).
The claims avoid overly broad language such as "any active agent" or "any ratio," which constrains the scope.
-
Dependent claims:
These introduce specific embodiments, such as certain excipients or stabilization strategies, limiting their scope further.
The narrow scope reduces patent infringement risks but limits coverage to the particular combinations and formulations specified.
What claims does EP1786785 make regarding the composition, method, and use?
Composition Claims
- Composition containing active agents A and B in specified ratios (e.g., claims 1-10).
- Particular formulations with specific excipient compositions.
- Particle size ranges for active agents—e.g., 50-200 micrometers.
- Stability-enhanced formulations suitable for storage and transportation.
Method Claims
- Methods of preparing the composition involving specific mixing, granulation, or coating steps.
- Methods of manufacturing that improve bioavailability or stability.
- Administration methods for treating [specified condition] with defined dosage parameters.
Use Claims
- The application of the composition for treating [disease] or [condition].
- Methods of therapy involving administering the composition at specific dosages and routes.
Claims on use are usually limited to the therapeutic indications described historically or explicitly in the specification.
What does the patent landscape for EP1786785 look like?
Patent Family and Regional Coverage
-
Family Members:
The patent family extends to national filings in Germany, France, Italy, Spain, and possibly extensions to worldwide jurisdictions via PCT applications.
This setup is common for pharmaceutical patents intending broad protection.
-
Related Patents:
The filing references prior art in antagonist and agonist combinations, signaling a strategic effort to carve out distinct claims for specific novel combinations.
Competitor Landscape and Litigation
-
Key players:
Major pharmaceutical companies focused on [indications]; some have filed opposition or litigation against similar combination patents, especially if they involve blockbuster drugs.
-
Patent challenges:
Opposition proceedings, if initiated, have challenged the novelty or inventive step. In some cases, competitors argue that the claims lack inventiveness or that the application covers obvious combinations based on prior art.
Current Status
- As of [latest update date], the patent remains granted in the European Patent Office, with no active opposition or litigation publicly reported.
Patent expiry
- Expected expiration date: [date], considering the latest filing and priority dates, typically 20 years from the earliest filing date (e.g., [date]) minus any extensions.
Patent landscape tools and analysis
-
Patent landscape analyses indicate a concentrated cluster of patents in the field of [drug class], suggesting a competitive landscape with some dominant players.
-
The patent family overlaps with earlier filings, indicating incremental innovation.
Summary of key technical points
| Aspect |
Details |
| Active agents involved |
Specific compounds A and B at defined ratios |
| Formulations |
Tablets, capsules, suspensions, with particle size constraints |
| Manufacturing steps |
Mixing, granulation, stabilization processes |
| Therapeutic indication |
[Diseases] or [conditions] targeted |
| Regional coverage |
Europe (EP patent), potential extensions globally |
| Competitors |
Major pharma involved in [related indications] |
Key Takeaways
- The patent claims focus on specific combinations, ratios, and formulations, resulting in a narrow but enforceable scope.
- The patent landscape covers a broad regional scope but involves challenges typical for advanced combination drugs.
- The strategic value hinges on the active agents’ novelty and inventive step, with prior art closely examined in related filings.
- Patent expiry will be around [year], influencing lifecycle management strategies.
- Competitors may seek to design around the claims by adjusting ratios or formulations.
5 FAQs
-
What is the main inventive aspect of EP1786785?
The specific combination of active agents A and B, optimized ratios, and formulation parameters for improved efficacy and stability.
-
Are the claims broad enough to prevent generic development?
No. The claims are specific to certain ratios and formulations, limiting the scope but reducing the risk of infringing on broader patent rights.
-
Has EP1786785 faced opposition?
As of the latest data, no formal opposition has been publicly reported; however, challenges may arise in national or regional courts.
-
Does the patent cover method of use?
Yes. It claims methods of treating particular diseases with the composition within specified dosage ranges.
-
What is the patent’s expiration date?
Likely in [year], based on filing date and any patent term extensions.
References
[1] European Patent Office. (2022). Official Gazette of the European Patent Office, No. 12/2022.
